2023
Hepatopancreatobiliary malignancies: time to treatment matters
Kerekes D, Frey A, Bakkila B, Johnson C, Becher R, Billingsley K, Khan S. Hepatopancreatobiliary malignancies: time to treatment matters. Journal Of Gastrointestinal Oncology 2023, 0: 0-0. PMID: 37201090, PMCID: PMC10186552, DOI: 10.21037/jgo-22-1067.Peer-Reviewed Original ResearchTreatment initiationStage IHPB cancersStage I pancreatic cancerExtrahepatic bile duct cancerKaplan-Meier survival analysisHPB cancer patientsNational Cancer DatabaseRetrospective cohort studyBile duct cancerMedian treatment initiationHepatopancreatobiliary cancersMedian survivalCohort studyDuct cancerOverall survivalHispanic patientsEHBD cancerOncologic careBile ductCox regressionBlack raceCancer patientsDefinitive carePancreatic cancer
2019
Safety and Feasibility of Hepatic Artery Infusion Pump Chemotherapy for Unresectable Colorectal Liver Metastases: A Multicenter, Retrospective Cohort Study
Muaddi H, Fields R, Aucejo F, Billingsley K, Walker B, D'Angelica M, Latchana N, Roke R, Ko Y, Williams G, Acevedo-Moreno L, Mayo S, Karanicolas P. Safety and Feasibility of Hepatic Artery Infusion Pump Chemotherapy for Unresectable Colorectal Liver Metastases: A Multicenter, Retrospective Cohort Study. Journal Of The American College Of Surgeons 2019, 229: s184. DOI: 10.1016/j.jamcollsurg.2019.08.406.Peer-Reviewed Original Research
2016
Nomogram for Predicting Overall Survival and Salvage Abdominoperineal Resection for Patients with Anal Cancer
Tsikitis VL, Lu KC, Kim JS, Billingsley KG, Thomas CR, Herzig DO. Nomogram for Predicting Overall Survival and Salvage Abdominoperineal Resection for Patients with Anal Cancer. Diseases Of The Colon & Rectum 2016, 59: 1-7. PMID: 26651105, DOI: 10.1097/dcr.0000000000000507.Peer-Reviewed Original ResearchSalvage abdominoperineal resectionAbdominoperineal resectionOverall survivalAnal cancerSalvage surgeryNodal statusTumor sizeStratified Cox proportional hazards modelCox proportional hazards modelAnal cancer treatmentNational Cancer DatabaseRetrospective cohort studyAnal cancer patientsYear of diagnosisTNM clinical stagePredicting Overall SurvivalOverall survival modelProportional hazards modelLogistic regression modelsSphincter preservationChemoradiation therapyCohort studySurgery statusChemoradiotherapy treatmentClinical stage
2005
Explaining Black–White Differences in Receipt of Recommended Colon Cancer Treatment
Baldwin L, Dobie S, Billingsley K, Cai Y, Wright G, Dominitz J, Barlow W, Warren J, Taplin S. Explaining Black–White Differences in Receipt of Recommended Colon Cancer Treatment. Journal Of The National Cancer Institute 2005, 97: 1211-1220. PMID: 16106026, PMCID: PMC3138542, DOI: 10.1093/jnci/dji241.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlack or African AmericanChemotherapy, AdjuvantCohort StudiesColonic NeoplasmsComorbidityFemaleHealth Services AccessibilityHumansLength of StayMaleMedicareOdds RatioPractice Patterns, Physicians'Retrospective StudiesRisk FactorsSEER ProgramSeverity of Illness IndexSocial SupportSocioeconomic FactorsUnited StatesWhite PeopleConceptsHealth system factorsBlack-White disparitiesChemotherapy receiptWhite patientsMedical oncologistsBlack patientsCancer treatmentRetrospective cohort studyBlack-white differencesColon cancer resectionAmerican Medical Association MasterfileEnd Results ProgramColorectal cancer treatmentColon cancer careColon cancer patientsLogistic regression analysisSystem factorsRegression analysisNeighborhood socioeconomic statusColon cancer treatmentAdjuvant chemotherapyChemotherapy useCohort studyCancer resectionIllness severity
2002
Race, Treatment, and Survival of Veterans With Cancer of the Distal Esophagus and Gastric Cardia
Dominitz J, Maynard C, Billingsley K, Boyko E. Race, Treatment, and Survival of Veterans With Cancer of the Distal Esophagus and Gastric Cardia. Medical Care 2002, 40: i-14. PMID: 11789626, DOI: 10.1097/00005650-200201001-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBlack or African AmericanCarcinoma, Squamous CellCardiaChemotherapy, AdjuvantCohort StudiesEsophageal NeoplasmsEsophagectomyEsophagogastric JunctionHealth Services AccessibilityHealth Services ResearchHospitals, VeteransHumansMaleProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival AnalysisUnited StatesVeteransWhite PeopleConceptsSquamous cell carcinomaDistal esophageal cancerSurgical resectionBlack patientsRadiation therapyEsophageal cancerEsophageal adenocarcinomaEqual‐access medical systemWhite veteransVeterans Affairs Medical CenterBlack male veteransDistal esophageal adenocarcinomaSurvival of veteransRetrospective cohort studySurvival of patientsCohort studyGastric cardiaDistal esophagusSimilar oddsCell carcinomaCancer survivalMedical CenterInvasive proceduresLower oddsSimilar survival
2001
The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population
Billingsley K, Maynard C, Schwartz D, Dominitz J. The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population. Cancer 2001, 92: 1272-1280. PMID: 11571743, DOI: 10.1002/1097-0142(20010901)92:5<1272::aid-cncr1448>3.0.co;2-a.Peer-Reviewed Original ResearchConceptsOperable esophageal carcinomaTrimodality therapyEsophageal carcinomaPerioperative mortalityDistal esophageal tumorsOutpatient clinic filesOutcomes of patientsRetrospective cohort studyOverall perioperative mortalityFavorable prognostic factorPredictors of survivalAbsence of metastasesMain outcome measuresPatient Treatment FileRecord Locator SystemType of treatmentHealth care systemInduction chemoradiotherapyMidesophageal tumorsNeoadjuvant chemoradiotherapyCohort studyMedian survivalOverall survivalPatient ageSurgical therapy